# Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

> **NCT00782561** · PHASE1 · TERMINATED · sponsor: **Kyntra Bio** · enrollment: 2 (actual)

## Conditions studied

- Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** FG-3019

## Key facts

- **NCT ID:** NCT00782561
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2009-06-18
- **Final completion:** 2009-06-18
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782561, "Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00782561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*